<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650451</url>
  </required_header>
  <id_info>
    <org_study_id>BPX603-201A</org_study_id>
    <nct_id>NCT04650451</nct_id>
  </id_info>
  <brief_title>Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors</brief_title>
  <official_title>A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety,&#xD;
      tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603,&#xD;
      administered with rimiducid to subjects with previously treated, locally advanced or&#xD;
      metastatic solid tumors which are HER2 amplified/overexpressed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Phase 1: Cell dose escalation to identify the maximum dose of BPX-603 administered&#xD;
           without or with rimiducid (fixed dose at 0.4 mg/kg per infusion). The first subject in&#xD;
           each dose cohort will receive BPX-603 alone (without rimiducid) in order to assess&#xD;
           safety of the CAR-T monotherapy.&#xD;
&#xD;
        -  Phase 2: Indication-specific dose expansion to assess the safety, pharmacodynamics&#xD;
           (including BPX-603 persistence and response to temsirolimus as applicable), and clinical&#xD;
           activity at the recommended dose for expansion (RDE) identified in Phase 1 in various&#xD;
           HER2+ solid tumors.&#xD;
&#xD;
        -  During Phase 1 or 2, temsirolimus (single IV dose at 25 mg) may be administered&#xD;
           following BPX-603 infusion in response to treatment-emergent toxicity in order to&#xD;
           activate the iRC9 safety switch.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">January 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of BPX-603</measure>
    <time_frame>35 days from time of BPX-603 infusion</time_frame>
    <description>Dose limiting toxicities are defined as BPX-603-related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)</measure>
    <time_frame>through Phase 1 completion, up to 2 years</time_frame>
    <description>Identify the optimal dose of BPX-603 for Phase 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of HER2-CAR T cells (cell counts)</measure>
    <time_frame>measured over time from baseline through study completion, up to 5 years</time_frame>
    <description>The persistence over time of BPX-603 CAR T cells in the peripheral blood as determined by flow cytometry (% CAR+ cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion of HER2-CAR T cells (vector copy number)</measure>
    <time_frame>measured over time from baseline through study completion, up to 5 years</time_frame>
    <description>The expansion over time of BPX-603 CAR T cells in the peripheral blood as determined by qPCR (copies/ug gDNA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of BPX-603</measure>
    <time_frame>through study completion, up to 5 years</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>HER-2 Gene Amplification</condition>
  <condition>HER2-positive Gastric Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>HER-2 Protein Overexpression</condition>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>HER2-targeted dual-switch CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>chimeric antigen receptor (CAR) T cell therapy</intervention_name>
    <description>HER2-targeted dual-switch CAR-T cells</description>
    <arm_group_label>HER2-targeted dual-switch CAR-T cells</arm_group_label>
    <other_name>CAR-T</other_name>
    <other_name>BPX-603</other_name>
    <other_name>autologous CAR-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented evidence of HER2 amplification/overexpression by local testing.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of a locally advanced unresectable&#xD;
             or metastatic HER2+ solid tumor malignancy for which standard treatment is no longer&#xD;
             effective, does not exist, or subject is ineligible.&#xD;
&#xD;
          -  Subjects with a solid tumor malignancy for which HER2-targeted therapy is approved as&#xD;
             a standard treatment (e.g., breast, gastric cancers) must have received prior&#xD;
             treatment with approved HER2-directed therapy.&#xD;
&#xD;
          -  Measurable disease (at least one target lesion) per RECIST v1.1.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  ECOG 0-1.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing central nervous system metastases.&#xD;
&#xD;
          -  Prior CAR T cell or other genetically-modified T cell therapy.&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
          -  Symptomatic intrinsic lung disease or those with extensive tumor involvement of the&#xD;
             lungs.&#xD;
&#xD;
          -  Severe intercurrent infection.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Known HIV positivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BPX-603 Study Team</last_name>
    <phone>832-384-1100</phone>
    <email>603enrolment@bellicum.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Yuan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yuan Yuan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute at Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>322972</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Akce, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mehmet Akce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Grand'Maison, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ann Grand'Maison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bharti Rathore, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bharti Rathore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ecaterina I Dumbrava, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ecaterina I Dumbrava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>CAR-T</keyword>
  <keyword>breast cancer</keyword>
  <keyword>solid tumors</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

